Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Breast Cancer
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Breast Cancer
    Insulin-Like Growth Factor Predicts Poor Outcome in Breast Cancer - (DGNews)
    TopAbstracts in Breast Cancer 08/26/2008 - (DGNews)
    Bilateral Paraesthesia Common With Paclitaxel Treatment for Early Breast Cancer: Presented at WCP - (DGDispatch)
    FDA Investigating Possible Link Between Ezetimibe/Simvastatin and Increased Cancer Risk - (DGNews)
    Endocrine Therapy Plus Zoledronic Acid Improves BMD in Premenopausal Women With Early Breast Cancer - (DGNews)

    News archive

     Recent webcasts/CME - Breast Cancer
  • Chemotherapy Resistance in Breast Cancer: Which Mechanisms Have Clinical Relevance?
  • Breast Problems:  Common Problems in Adults (non-pregnant)

    Webcasts/CME archive

     Recent cases - Breast Cancer
      A Case of Matrix-Producing Carcinoma of the Breast
      Metastatic Hurthle Cell Carcinoma of the Thyroid Presenting as a Breast Lump: A Case Report
      Paraneoplastic Cerebellar Degeneration as a Presentation of Breast Cancer - A Case Report and Review of the Literature
      Primary Lymphoma of the Breast Involving Both Axillae with Bilateral Breast Carcinoma
      An Unusually Large Myofibroblastoma in a Male Breast: A Case Report

      Cases archive
        




      my personal edition > breast cancer > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Survival After Breast Cancer Brain Metastases About 13.9 Months: Presented at SABCS

      By Ed Susman

      SAN ANTONIO, TX -- December 17, 2007 -- Researchers mining the dataset from the registHER study -- an observational cohort of about 1,000 women with HER2-positive metastatic breast cancer -- reported that the median survival after detection of brain metastasis is about 13.9 months.

      The researchers also found that brain metastases occur in about 30% of women, and also occur relatively early -- after a median of 12.1 months following the diagnosis that the cancer has spread, said Denise Yardley, MD, Director, Breast Cancer Research Program, Sarah Cannon Research Institute, Nashville, Tennessee.

      "RegistHER represents the largest dataset of patients with HER2-positive metastatic breast cancer and provides a unique opportunity to characterize the natural history of this important subset of patients," Dr. Yardley said on December 16 here at the 30th Annual San Antonio Breast Cancer Symposium (SABCS).

      The study enrolled 1,023 women between December 2003 and February 2006. Dr. Yardley's team analyzed 768 of these women, who were diagnosed with metastatic disease. Of this group, 236 women (30.7%) were diagnosed with central nervous system metastases.

      These HER2-positive patients who developed central nervous system metastases were more likely to be young, to have hormone-receptor-negative disease, and to have higher disease burden, Dr. Yardley said.

      About 39.7% of the patients were on their first line of chemotherapy when they were diagnosed with central nervous system metastases; 32.1% were on their second line of treatment; 16.8% of patients were into their third line of treatment.

      Among patients who had a central nervous system metastases at the time of diagnosis, about three fourths had a trastuzumab-containing first-line regimen; 5.8% of these women received a chemotherapy- or hormone-containing first-line treatment; 17.3% did not receive a first-line treatment but were receiving treatment before their first progressive event.

      Funding for this study was provided by Genentech, Inc.


      [Presentation title: RegistHER: Patient Characteristics and Time Course of CNS Metastases in Patients With HER2-Positive Metastatic Breast Cancer. Abstract 6049]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send